ALLO - Company ID 0001737287
Allogene Therapeutics, Inc. trades as ALLO. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$190.89M. This page tracks Allogene Therapeutics, Inc. through 554 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -159.6% to -1170863.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Proxy materials | DEFA14A | 2026-05-21 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| Annual report to shareholders | ARS | 2026-04-30 |
The largest companies sharing Allogene Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Allogene Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
In its latest fiscal year Allogene Therapeutics, Inc. reported a net loss of $190.89M.